UK Companies House feature
CHEMIDEX PHARMA LIMITED
Cash
£8M
-35.4% vs 2021
Net assets
£28M
+71.3% vs 2021
Employees
33
+26.9% vs 2021
Profit before tax
£27M
+65.6% vs 2021
Profile
- Company number
- 01676110
- Status
- Active
- Incorporation
- 1982-11-08
- Last accounts made up
- 2024-06-30
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Net assets
2-year trend · vs UK Healthcare median
Accounts
2-year trend · latest 2022-06-30
| Metric | Trend | 2021-06-30 | 2022-06-30 |
|---|---|---|---|
| Turnover | £33,000,551 | £30,681,464 | |
| Operating profit | £15,500,705 | £25,654,108 | |
| Profit before tax | £16,217,306 | £26,860,273 | |
| Net profit | — | — | |
| Cash | £12,716,273 | £8,209,459 | |
| Total assets less current liabilities | £16,525,101 | £28,186,252 | |
| Net assets | £16,363,810 | £28,024,961 | |
| Equity | £16,363,810 | £28,024,961 | |
| Average employees | 26 | 33 | |
| Wages | — | — |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Having considered the above, the directors have concluded that the group is well placed to manage the business risks, able to meeting its obligations and covenant requirements throughout the going concern assessment period being 12 months from the approval of these financial statements, and therefore adopts the going concern basis in preparing these financial statements.”
Subsidiaries
- Essential Pharma Switzerland GmbH · 100% held · Switzerland
Significant events
- “In December 2023, the group acquired the European rights to Colobreathe®, an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, and is the first rare disease medicine to be added to the product portfolio.”
- “In April 2024, the group acquired the rights to Reminyl® oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America. Reminyl® is an established central nervous system (CNS) brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type and is a significant addition to the product portfolio of specialty CNS medicines and further expands the company's presence globally.”
- “To help fund the acquisition of the above, the group issued variable rate unsecured loan notes of £79.7m expiring in December 2025.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| RAMSDEN, Simon Stanley, Mr. | Director | 2025-09-29 | Dec 1981 | British |
| WEBB, Andrew Michael, Mr. | Director | 2022-05-01 | Jun 1983 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ENGINEER, Misha | Secretary | 2013-03-27 | 2014-10-17 |
| ENGINEER, Navinchandra Jamnadas | Secretary | — | 2013-03-28 |
| ASH, Benjamin Matthew | Director | 2020-04-17 | 2025-06-27 |
| ENGINEER, Misha | Director | 2013-03-15 | 2014-10-17 |
| ENGINEER, Navinchandra Jamnadas | Director | — | 2013-03-28 |
| ENGINEER, Nikesh | Director | 2012-11-02 | 2021-06-22 |
| ENGINEER, Varsha Navinchandra | Director | — | 2013-03-28 |
| JOHNSON, Emma Jane | Director | 2023-07-01 | 2025-11-10 |
| LIBORG, Ingvild | Director | 2020-04-17 | 2022-04-30 |
| VANGSGAARD, Steen | Director | 2021-06-22 | 2023-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Cortex 3 Guernsey Limited | Corporate entity | Shares 25–50% | 2019-12-16 | Ceased 2019-12-16 |
| Guy Semmens | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-12-16 | Active |
| Mr Navinchandra Jamnadas Engineer | Individual | Shares 50–75% | 2016-04-06 | Ceased 2019-12-16 |
| Mrs Varsha Navinchandra Engineer | Individual | Shares 25–50% | 2016-04-06 | Ceased 2019-12-16 |
Filing timeline
Last 20 of 163 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-11-27 | TM01 | officers | termination director company with name termination date |
| 2025-09-30 | AP01 | officers | appoint person director company with name date |
| 2025-07-22 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-07-08 | TM01 | officers | termination director company with name termination date |
| 2025-04-02 | AA | accounts | accounts with accounts type full |
| 2025-04-02 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2025-04-02 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-12-11 | MR04 | mortgage | mortgage satisfy charge full |
| 2024-12-11 | MR04 | mortgage | mortgage satisfy charge full |
| 2024-12-11 | MR04 | mortgage | mortgage satisfy charge full |
| 2024-12-11 | MR04 | mortgage | mortgage satisfy charge full |
| 2024-09-13 | PSC04 | persons-with-significant-control | change to a person with significant control |
| 2024-07-25 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-07-15 | AD01 | address | change registered office address company with date old address new address |
| 2024-03-27 | AA | accounts | accounts with accounts type full |
| 2024-03-05 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2024-02-23 | RP04PSC01 | persons-with-significant-control | second filing notification of a person with significant control |
| 2023-07-18 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-07-18 | AP01 | officers | appoint person director company with name date |
| 2023-07-18 | TM01 | officers | termination director company with name termination date |
Credit score
Altman Z″ (private-firm) · reference 2022-06-30
7.24
SAFE
Altman Z″
- Working capital / Total assets 0.481 × 6.56 = +3.16
- Retained earnings / Total assets 0.000 × 3.26 = +0.00
- EBIT / Total assets 0.454 × 6.72 = +3.05
- Book equity / Total liabilities 0.982 × 1.05 = +1.03
Bands: > 2.6 safe · 1.1–2.6 grey · < 1.1 distress. Z″ is a public-formula baseline, not a substitute for adverse-data signals (CCJs, charges, gazette notices) — those land in a later pass.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory